Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TLR4 | O00206 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14668228 | 0.86 | KDM4E (0.32) | — | |
| SCHEMBL14668233 | 0.85 | THRB (0.36) | — | |
| (-)-Piperitone SCHEMBL1248697 | 0.80 | TLR4 (0.40) | TLR4 | |
| Piperitone SCHEMBL111913 | 0.80 | TLR4 (0.40) | TLR4 | |
| SCHEMBL11458638 | 0.78 | ACE (0.39) | ACETSHRPTGS1PTGS2OPRK1 | |
| SCHEMBL11702706 | 0.72 | ACE (0.35) | ACE | |
| SCHEMBL31391968 | 0.71 | TAS2R46 (0.41) | PPARATLR4TSHRMAPTPTGS2 | |
| SCHEMBL11703281 | 0.70 | ACE (0.41) | ACETSHR | |
| Piperitone SCHEMBL14763689 | 0.69 | PTPN2 (0.35) | TLR4 | |
| SCHEMBL17530030 | 0.67 | ACE (0.51) | ACETSHRMAPTPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-09-19 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481759-B2 | Process for producing wine lactone | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | TAKASAGO INTERNATIONAL CORPORATION | 2013-01-31 | — | — | US | disclosed |
| US-4008270-A | Process for preparing 2-(substituted phenyl)propionic acids | THE UPJOHN COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245286-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | ACE 3156/4885PPARG 1124/4885PPARA 874/4885 |
| US-20130245287-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | ACE 3156/4885PPARG 1124/4885PPARA 874/4885 |
| US-20130030193-A1 | PROCESS FOR PRODUCING WINE LACTONE | SUCLA2, ADH5, PCCA | ACE 3156/4885PPARG 1124/4885PPARA 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.